CY1118100T1 - Διαλυμα ατομοξετινης - Google Patents
Διαλυμα ατομοξετινηςInfo
- Publication number
- CY1118100T1 CY1118100T1 CY20161101032T CY161101032T CY1118100T1 CY 1118100 T1 CY1118100 T1 CY 1118100T1 CY 20161101032 T CY20161101032 T CY 20161101032T CY 161101032 T CY161101032 T CY 161101032T CY 1118100 T1 CY1118100 T1 CY 1118100T1
- Authority
- CY
- Cyprus
- Prior art keywords
- atomoxetine
- aqueous solution
- atomoxetine solution
- solution
- young
- Prior art date
Links
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 title abstract 3
- 229960002430 atomoxetine Drugs 0.000 title abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 235000019658 bitter taste Nutrition 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901577P | 2013-11-08 | 2013-11-08 | |
| PCT/US2013/076435 WO2014204513A1 (en) | 2013-11-08 | 2013-12-19 | Atomoxetine solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118100T1 true CY1118100T1 (el) | 2017-06-28 |
Family
ID=49920679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101032T CY1118100T1 (el) | 2013-11-08 | 2016-10-13 | Διαλυμα ατομοξετινης |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9326935B2 (https=) |
| EP (1) | EP2838510B1 (https=) |
| JP (1) | JP5973073B2 (https=) |
| CN (1) | CN105705135A (https=) |
| CY (1) | CY1118100T1 (https=) |
| DK (1) | DK2838510T3 (https=) |
| ES (1) | ES2605495T3 (https=) |
| HU (1) | HUE032205T2 (https=) |
| IL (1) | IL244878A (https=) |
| MX (1) | MX365663B (https=) |
| PL (1) | PL2838510T3 (https=) |
| PT (1) | PT2838510T (https=) |
| SI (1) | SI2838510T1 (https=) |
| TW (1) | TWI583402B (https=) |
| WO (1) | WO2014204513A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726473A (zh) * | 2016-03-31 | 2016-07-06 | 北京万全德众医药生物技术有限公司 | 托莫西汀或其可药用盐口服溶液及其制备方法 |
| CN106727291B (zh) * | 2016-12-06 | 2020-02-11 | 山东达因海洋生物制药股份有限公司 | 一种盐酸托莫西汀口服溶液及其制备方法 |
| US9855228B1 (en) * | 2016-12-14 | 2018-01-02 | Taho Pharmaceuticals Ltd. | Oral solution comprising atomoxetine hydrochloride and methods thereof |
| CN111437247A (zh) * | 2019-01-17 | 2020-07-24 | 北京万全德众医药生物技术有限公司 | 一种托莫西汀口服液的制备方法 |
| CN112438949A (zh) * | 2019-09-05 | 2021-03-05 | 北京兴源联合医药科技有限公司 | 一种含钙补充剂的盐酸托莫西汀口服液及其制备方法 |
| CN112451476A (zh) * | 2019-09-09 | 2021-03-09 | 北京兴源联合医药科技有限公司 | 一种盐酸托莫西汀口服液及其制备方法 |
| CN111956607A (zh) * | 2020-09-25 | 2020-11-20 | 健民药业集团股份有限公司 | 盐酸托莫西汀口服溶液及其制备方法 |
| CN115869253A (zh) * | 2021-09-28 | 2023-03-31 | 郑州深蓝海生物医药科技有限公司 | 一种盐酸托莫西汀口服溶液及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR75395B (https=) | 1980-11-14 | 1984-07-13 | Lilly Co Eli | |
| US5658590A (en) | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| AU4529101A (en) * | 2000-03-07 | 2001-09-17 | Eli Lilly And Company | Treatment of psoriasis |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| AU2004312059A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
| CN101155775A (zh) * | 2005-04-05 | 2008-04-02 | 特瓦药物精化学品股份有限公司 | 稳定的阿托莫西汀盐酸盐、其制备方法，以及其稳定性分析控制 |
| JP2008501721A (ja) | 2005-04-05 | 2008-01-24 | テバ ファーマシューティカル ファイン ケミカルズ ソチエタ レスポンサビリタ リミテ | 安定性アトモキセチン塩酸塩、その調製方法及びその安定性の分析的調節 |
| US20070134277A1 (en) * | 2005-12-09 | 2007-06-14 | Children's Medical Center Corporation | Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms |
| WO2007103687A2 (en) | 2006-03-01 | 2007-09-13 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
| US20080031932A1 (en) | 2006-08-04 | 2008-02-07 | Watson Laboratories, Inc. | Transdermal atomoxetine formulations and associated methods |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| US20080145318A1 (en) | 2006-12-13 | 2008-06-19 | Midha Kamal K | Atomoxetine formulations and associated methods |
| EP2512460A4 (en) | 2009-12-18 | 2015-01-21 | Exodos Life Sciences Ltd Partnership | METHOD AND COMPOSITIONS FOR STABLE LIQUID ACTIVE FORMULATIONS |
| JP5902148B2 (ja) | 2010-03-31 | 2016-04-13 | アベラ ファーマスーティカルズ インコーポレイテッド | 自閉症治療用ジメチルスルホキシド（ｄｍｓｏ）製剤 |
| BR112013033239A2 (pt) | 2011-06-22 | 2016-09-06 | Vyome Biosciences | pró-farmácos de conjugado baseado em atifungicos e antibacterianos |
| US9040082B2 (en) | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
| US20120128683A1 (en) | 2011-11-22 | 2012-05-24 | Shantha Totada R | Autism treatment |
-
2013
- 2013-12-19 JP JP2015523309A patent/JP5973073B2/ja active Active
- 2013-12-19 PT PT138181821T patent/PT2838510T/pt unknown
- 2013-12-19 MX MX2016005998A patent/MX365663B/es active IP Right Grant
- 2013-12-19 DK DK13818182.1T patent/DK2838510T3/en active
- 2013-12-19 PL PL13818182T patent/PL2838510T3/pl unknown
- 2013-12-19 HU HUE13818182A patent/HUE032205T2/en unknown
- 2013-12-19 US US14/134,183 patent/US9326935B2/en active Active
- 2013-12-19 EP EP13818182.1A patent/EP2838510B1/en not_active Revoked
- 2013-12-19 WO PCT/US2013/076435 patent/WO2014204513A1/en not_active Ceased
- 2013-12-19 CN CN201380080783.2A patent/CN105705135A/zh active Pending
- 2013-12-19 SI SI201330306A patent/SI2838510T1/sl unknown
- 2013-12-19 ES ES13818182.1T patent/ES2605495T3/es active Active
-
2014
- 2014-01-10 TW TW103101018A patent/TWI583402B/zh active
-
2016
- 2016-04-04 IL IL244878A patent/IL244878A/en active IP Right Grant
- 2016-10-13 CY CY20161101032T patent/CY1118100T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5973073B2 (ja) | 2016-08-23 |
| JP2015522624A (ja) | 2015-08-06 |
| TW201431567A (zh) | 2014-08-16 |
| MX2016005998A (es) | 2016-07-18 |
| WO2014204513A1 (en) | 2014-12-24 |
| US20150133562A1 (en) | 2015-05-14 |
| ES2605495T3 (es) | 2017-03-14 |
| US9326935B2 (en) | 2016-05-03 |
| TWI583402B (zh) | 2017-05-21 |
| CN105705135A (zh) | 2016-06-22 |
| DK2838510T3 (en) | 2016-12-19 |
| EP2838510A1 (en) | 2015-02-25 |
| IL244878A0 (en) | 2016-05-31 |
| IL244878A (en) | 2017-04-30 |
| EP2838510B1 (en) | 2016-09-21 |
| MX365663B (es) | 2019-06-10 |
| SI2838510T1 (sl) | 2016-11-30 |
| PT2838510T (pt) | 2016-11-23 |
| HUE032205T2 (en) | 2017-09-28 |
| PL2838510T3 (pl) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118100T1 (el) | Διαλυμα ατομοξετινης | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| ECSP17084331A (es) | Formulaciones farmacéuticas | |
| CY1121736T1 (el) | Άλατα aramchol | |
| EP3469931A4 (en) | AROMA INHALER AND COMBUSTION TYPE SOURCE OF HEAT | |
| CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| EA201592227A1 (ru) | Стабильные растворы объединенных активных фармацевтических ингредиентов для перорального применения | |
| SI3069720T1 (sl) | Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni | |
| BR112014000347A2 (pt) | método para melhorar o aroma de um alimento, bebida, produto farmacêutico ou produto para o cuidado oral, e, alimento, bebida, produto farmacêutico ou produto para o cuidado oral | |
| JP2017537912A5 (https=) | ||
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| DK3302543T3 (da) | Vaccinesammensætninger mod porcint reproduktions- og respirationssyndrom og porcint circovirus-associerede sygdomme | |
| DK3157506T3 (da) | Smagsmaskeret oral, farmaceutisk sammensætning | |
| MX2015014309A (es) | Modulador de sabor y metodo para utilizar el mismo. | |
| CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
| BR112017026306A2 (pt) | embalagem para instrumento para higiene bucal. | |
| EP3141264A4 (en) | Pharmaceutical preparation for masked taste oral administration, containing clomipramine | |
| JP2016513537A5 (https=) | ||
| TR201618030T2 (tr) | Tadı düzeltilmiş parasetamol formülasyonları. | |
| PH12015500708A1 (en) | Agent for enhancing immunity containing glutathione | |
| 姜华瑞 | A Study of Defamiliarization in Midnitht's Children | |
| CR20170601A (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
| CN302533794S (zh) | 包装袋（三分钟微波鱼片麻辣味） |